JP2008508279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508279A5 JP2008508279A5 JP2007523596A JP2007523596A JP2008508279A5 JP 2008508279 A5 JP2008508279 A5 JP 2008508279A5 JP 2007523596 A JP2007523596 A JP 2007523596A JP 2007523596 A JP2007523596 A JP 2007523596A JP 2008508279 A5 JP2008508279 A5 JP 2008508279A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dosage form
- vitamin
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 238000013268 sustained release Methods 0.000 claims 9
- 239000012730 sustained-release form Substances 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 239000006203 subcutaneous dosage form Substances 0.000 claims 5
- 229930003316 Vitamin D Natural products 0.000 claims 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 4
- 235000019166 vitamin D Nutrition 0.000 claims 4
- 239000011710 vitamin D Substances 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- 229940046008 vitamin d Drugs 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 102000009310 vitamin D receptors Human genes 0.000 claims 3
- 108050000156 vitamin D receptors Proteins 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002478 aldosterone Drugs 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 235000020964 calcitriol Nutrition 0.000 claims 2
- 239000011612 calcitriol Substances 0.000 claims 2
- 229960005084 calcitriol Drugs 0.000 claims 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 2
- 229960002061 ergocalciferol Drugs 0.000 claims 2
- 229960000987 paricalcitol Drugs 0.000 claims 2
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 235000001892 vitamin D2 Nutrition 0.000 claims 2
- 239000011653 vitamin D2 Substances 0.000 claims 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/901,660 US20050148557A1 (en) | 2003-07-29 | 2004-07-28 | Use of Vitamin Ds to treat kidney disease |
| US10/974,243 US20050124591A1 (en) | 2003-07-29 | 2004-10-27 | Use of vitamin Ds to treat kidney disease |
| PCT/US2005/024446 WO2006019659A1 (en) | 2004-07-28 | 2005-07-08 | Use of vitamin ds to treat kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508279A JP2008508279A (ja) | 2008-03-21 |
| JP2008508279A5 true JP2008508279A5 (enExample) | 2008-10-02 |
Family
ID=34982541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523596A Withdrawn JP2008508279A (ja) | 2004-07-28 | 2005-07-08 | 腎疾患を治療するためのビタミンｄの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050124591A1 (enExample) |
| EP (1) | EP1786407A1 (enExample) |
| JP (1) | JP2008508279A (enExample) |
| CA (1) | CA2575155A1 (enExample) |
| WO (1) | WO2006019659A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001969A1 (en) * | 2005-06-27 | 2007-01-04 | The General Hospital Corporation | Vitamin d deficiency and dialysis |
| CA2924200C (en) * | 2005-10-12 | 2017-09-05 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| PT3357496T (pt) | 2006-06-21 | 2020-05-12 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
| WO2008103420A1 (en) * | 2007-02-21 | 2008-08-28 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
| US8592401B2 (en) * | 2007-04-25 | 2013-11-26 | Proventiv Therapeutics, Llc | Methods and compounds for vitamin D therapy |
| CN101668532B (zh) * | 2007-04-25 | 2014-08-20 | 赛特克罗公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途 |
| PL3225243T3 (pl) | 2007-04-25 | 2025-12-22 | Opko Renal, Llc | Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek |
| KR20190141269A (ko) | 2007-04-25 | 2019-12-23 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| US8318708B2 (en) * | 2007-11-06 | 2012-11-27 | Salk Institute For Biological Studies | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis |
| US20090209500A1 (en) * | 2007-11-06 | 2009-08-20 | The Salk Institute For Biological Studies | Use of vitamin d receptor agonists and precursors to treat fibrosis |
| CN102046812A (zh) | 2008-04-02 | 2011-05-04 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| EP2461815B1 (en) * | 2009-08-03 | 2014-10-22 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| CA2797537C (en) | 2010-03-29 | 2021-11-23 | Cytochroma Inc. | Use of 25-hydroxyvitamin d compound for reducing parathyroid levels |
| SG194636A1 (en) | 2011-04-25 | 2013-12-30 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| EA030211B1 (ru) | 2012-04-25 | 2018-07-31 | Регьюлэс Терапьютикс Инк. | Соединения на основе микрорнк и способы модулирования активности mir-21 |
| JP2015522015A (ja) | 2012-06-29 | 2015-08-03 | ウイスコンシン アラムニ リサーチ ファンデーション | 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| JP2016520572A (ja) | 2013-04-24 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ビタミンｄ受容体／ｓｍａｄゲノム回路は線維化反応を制御する |
| AU2014274864B2 (en) | 2013-06-05 | 2018-10-18 | Salk Institute For Biological Studies | Vitamin D receptor agonists to treat diseases involving CXCL12 activity |
| EP2818176A1 (en) * | 2013-06-27 | 2014-12-31 | Virbac | Composition for the treatment of progressive renal diseases |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US9539264B2 (en) | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| EP4596045A3 (en) | 2016-03-28 | 2025-10-15 | EirGen Pharma Ltd. | Methods of vitamin d treatment |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| ES2968898T3 (es) * | 2019-06-06 | 2024-05-14 | Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz | Método in vitro para detectar enfermedad renal |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747008B1 (en) * | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
| FR2825087B1 (fr) * | 2001-05-22 | 2005-01-14 | Galderma Res & Dev | Analogues de la vitamine d |
-
2004
- 2004-10-27 US US10/974,243 patent/US20050124591A1/en not_active Abandoned
-
2005
- 2005-07-08 WO PCT/US2005/024446 patent/WO2006019659A1/en not_active Ceased
- 2005-07-08 CA CA002575155A patent/CA2575155A1/en not_active Abandoned
- 2005-07-08 JP JP2007523596A patent/JP2008508279A/ja not_active Withdrawn
- 2005-07-08 EP EP05769600A patent/EP1786407A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508279A5 (enExample) | ||
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| JP2009539841A5 (enExample) | ||
| NO20074509L (no) | Kombinasjon av organiske forbindelser | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| EA200701575A1 (ru) | Формуляция леветирацетама длительного высвобождения | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| WO2005070462A3 (en) | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| JP2008538564A5 (enExample) | ||
| EA200501420A1 (ru) | Устройство доставки для лекарственной и клеточной терапии | |
| AR075148A1 (es) | Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| JP2006513184A5 (enExample) | ||
| WO2007111945A3 (en) | Method for management of diarrhea | |
| TN2011000227A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| NZ597317A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| RU2014129508A (ru) | Новая комбинация | |
| CN1812792A (zh) | 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 | |
| JP2009517411A5 (enExample) | ||
| ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form |